

Cover fig caption: Representative section of the superficial zones of articular cartilage from placebo and *Brachytemma calycinum D don* (BCD)-treated dogs showing matrix metalloproteinase 13 immunostaining (original magnification  $\times 100$ ). Morphometric analysis data are presented as box plot and were analysed using MannWhitney twotailed U test.  $p < 0.05$  is considered significant. See page 1182.

### Editor

Tore K Kvien

### Associate Editors

Francis Berenbaum  
Hans Bijlsma  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

### Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 7.188

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2010 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Newgen and printed in the UK on acid-free paper from sustainable forests by Latimer Trend, Plymouth

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to Annals of the Rheumatic Diseases Mercury International Ltd, 365 Blair Road, Avenel NJ 07001, USA.

## Editorial

- 941** Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes  
*A Gibofsky, Y Yazici*
- 943** Annals of the Rheumatic Diseases: an update  
*T K Kvien*

## Viewpoint

- 945** Cytokines in Sjögren's syndrome: potential therapeutic targets  
*N Roescher, P P Tak, G G Illei*

## Review 2010

- 949** Spondyloarthritis: state of the art and future perspectives  
*D van der Heijde, W P Maksymowych*
- 955** Self-management of rheumatic diseases: state of the art and future perspectives  
*M D Iversen, A Hammond, N Betteridge*

## Recommendations

- 964** EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs  
*J S Smolen, R Landewé, F C Breedveld, M Dougados, P Emery, C Gaujoux-Viala, S Gorter, R Knevel, J Nam, M Schoels, D Aletaha, M Buch, L Gossec, T Huizinga, J W J Bijlsma, G Burmester, B Combe, M Cutolo, C Gabay, J Gomez-Reino, M Kouloumas, T K Kvien, E Martin-Mola, I McInnes, K Pavelka, P van Riel, M Scholte, D L Scott, T Sokka, G Valesini, R van Vollenhoven, K L Winthrop, J Wong, A Zink, D van der Heijde*

## Clinical and epidemiological research

- 976** Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA  
*J L Nam, K L Winthrop, R F van Vollenhoven, K Pavelka, G Valesini, E M A Hensor, G Worthy, R Landewé, J S Smolen, P Emery, M H Buch*
- 987** Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis  
*R Knevel, M Schoels, T W J Huizinga, D Aletaha, G R Burmester, B Combe, R Landewé, J S Smolen, T Sokka, D M F M van der Heijde*
- 995** Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis  
*M Schoels, J Wong, D L Scott, A Zink, P Richards, R Landewé, J S Smolen, D Aletaha*
- 1004** Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis  
*C Gaujoux-Viala, J S Smolen, R Landewé, M Dougados, T K Kvien, E M Mola, M Scholte-Voshaar, P van Riel, L Gossec*

- 1010** Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis  
*S L Gorter, J W Bijlsma, M Cutolo, J Gomez-Reino, M Kouloumas, J S Smolen, R Landewé*
- 1015** Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases  
*M C van der Goes, J W G Jacobs, M Boers, T Andrews, M A M Blom-Bakkers, F Buttgerit, N Caeyers, E H Choy, M Cutolo, J A P Da Silva, L Guillemin, M Holland, J R Kirwan, J Rovinsky, K G Saag, G Severijns, S Webber, R Westhovens, J W J Bijlsma*
- 1022** Tumour necrosis factor  $\alpha$  -308G→A polymorphism is not associated with response to TNF $\alpha$  blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis  
*S Pavy, E J M Toonen, C Miceli-Richard, P Barrera, P L C M van Riel, L A Criswell, X Mariette, M J H Coenen*
- 1029** Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment  
*R J L Tan, L J Gibbons, C Potter, K L Hyrich, A W Morgan, A G Wilson, J D Isaacs, BRAGGSS, A Barton*
- 1036** Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis  
*M A Little, P Nightingale, C A Verburgh, T Hauser, K De Groot, C Savage, D Jayne, L Harper, on behalf of the European Vasculitis Study (EUVAS) Group*
- 1044** Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study  
*S M M Verstappen, M F Bakker, A H M Heurkens, M J van der Veen, A A Kruize, M A W Geurts, J W J Bijlsma, J W G Jacobs, on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group*

### MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



When you have finished with this please recycle it

- 1049** Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis  
 *A Hinks, S Eyre, X Ke, A Barton, P Martin, E Flynn, J Pacheham, Childhood Arthritis Prospective Study (CAPS), UKRAG Consortium, BSPAR Study Group, J Worthington, W Thomson*
- 1054** Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease  
*J I Robinson, J H Barrett, J C Taylor, YEAR Consortium, M Naven, D Corscadden, BRAGGSS, A Barton, A G Wilson, P Emery, J D Isaacs, A W Morgan*
- 1058** Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials  
*J S Smolen, D Aletaha, J C Grisar, T A Stamm, J T Sharp*
- 1065** Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor  $\alpha$  inhibitors  
*S J Pedersen, I J Sørensen, K-G A Hermann, O R Madsen, N Tvede, M S Hansen, G Thamsborg, L S Andersen, O Majgaard, A G Lofi, J Erlendsson, K Asmussen, J S Johansen, A G Jurik, J Möller, M Hasselquist, D Mikkelsen, T Skjædt, A Hansen, M Østergaard*
- 1072** Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis  
 *P Stolt, A Yahya, C Bengtsson, H Källberg, J Rönnelid, I Lundberg, L Klareskog, L Alfredsson; the EIRA Study Group*
- 1077** Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk  
*E W Karlson, LB Chibnik, P Kraft, J Cui, B T Keenan, B Ding, S Raychaudhuri, L Klareskog, L Alfredsson, R M Plenge*
- 1086** Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register  
*W G Dixon, K L Hyrich, K D Watson, M Lum, BSRBR Control Centre Consortium, D P M Symmons on behalf of the British Society for Rheumatology Biologics Register*
- 1092** Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study  
*V Smith, C Pizzorni, F De Keyser, S Decuman, J T Van Praet, E Deschepper, A Sulli, M Cutolo*
- 1097** Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year  
*A Jørgensen, K Stengaard-Pedersen, O Simonsen, M Pfeiffer-Jensen, C Eriksen, H Bliddal, N W Pedersen, S Bødtker, K Hørslev-Petersen, L Ø Snerum, N Egdud, H Frimer-Larsen*
- 1103** EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome  
*R Seror, P Ravaud, S J Bowman, G Baron, A Tzioufas, E Theander, J-E Gottenberg, H Bootsma, X Mariette, C Vitali; on behalf of the EULAR Sjögren's Task Force*
- 1110** The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis  
*D van der Woude, S W Syversen, E I H van der Voort, K N Verpoort, G L Goll, M P M van der Linden, A H M van der Helm-van Mil, DMFM van der Heijde, T W J Huizinga, T K Kvien, R E M Toes*
- 1117** Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept  
*M P Lisbona, J Maymó, J Perich, M Almirall, J Carbonell*
- 1123** Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost  
*A Boonen, T Brinkhuizen, R Landewé, D van der Heijde, J L Severens*
- 1129** Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study  
*E Keystone, M C Genovese, L Klareskog, E C Hsia, S Hall, P C Miranda, J Pazdur, S-C Bae, W Palmer, S Xu, M U Rahman*
- 1136** Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study  
*I Rua-Figueroa, O Arencibia-Mireles, M Elvira, C Erausquin, S Ojeda, F Francisco, A Naranjo, C Rodríguez-Gallego, I Garcia-Laorden, J Rodríguez-Perez, C Rodríguez-Lozano*
- 1140** High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis  
*O Kaloudi, F Bandinelli, E Filippucci, M L Conforti, I Miniati, S Guiducci, F Porta, A Candelieri, D Conforti, G Grassiri, W Grassi, M Matucci-Cerinic*
- 1144** Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial  
*A Hartkamp, R Geenen, G L R Godaert, M Bijl, J W J Bijlsma, RHW M Derksen*
- 1148** Hepatoprotective effect of tumour necrosis factor  $\alpha$  blockade in psoriatic arthritis: a cross-sectional study  
*M Seitz, S Reichenbach, B Möller, M Zwahlen, P M Villiger, J-F Dufour*
- 1151** Bone marrow lesions are related to dynamic knee loading in medial knee osteoarthritis  
*K L Bennell, M W Creaby, T V Wrigley, K-A Bowles, R S Hinman, F Cicuttini, D J Hunter*
- 1155** Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?  
*H Amital, Z Szekaneecz, G Szücs, K Dankó, E Nagy, T Csépany, E Kiss, J Rovensky, A Tuchynova, D Kozakova, A Doria, N Corrocher, N Agmon-Levin, V Barak, H Orbach, G Zandman-Goddard, Y Shoenfeld*
- 1158** Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate  
 *S B Cohen, E Keystone, M C Genovese, P Emery, C Peterfy, P P Tak, M Cravets, T Shaw, D Hagerty*
- 1162** Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study  
*M A De Vera, M M Rahman, V Bhole, J A Kopec, H K Choi*


**1165** Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study  
*J-H Kang, Y-H Chen, H-C Lin*

**1169** Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy  
*J Lorenzen, S Lovric, R Krämer, H Haller, M Haubitz*

### Basic and translational research

**1172** Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint  
*M Biniecka, A Kennedy, U Fearon, C T Ng, D J Veale, J N O'Sullivan*


**1179** Oral treatment with a Brachyctemma calycinum D don plant extract reduces disease symptoms and the development of cartilage lesions in experimental dog osteoarthritis: inhibition of protease-activated receptor 2  
*C Boileau, J Martel-Pelletier, J Caron, F Paré, E Troncy, M Moreau, J-P Pelletier*

 **1185** Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss  
*K Kaur, R Hardy, M M Ahasan, M Eijken, J P van Leeuwen, A Filer, A M Thomas, K Raza, C D Buckley, P M Stewart, E H Rabbit, M Hewison, M S Cooper*

**1191** A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility  
*I Marinou, K Walters, J Winfield, D E Bax, A G Wilson*

**1195** Toll-like receptor 7 (TLR7) modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells  
*Z-j Pan, S Maier, K Schwarz, J Azbill, S Akira, S Uematsu, A D Farris*

**1200** Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis  
*H M Baldwin, T Ito-Ihara, J D Isaacs, C M U Hilkens*

 **1208** Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis  
*P A Lyons, E F McKinney, T F Rayner, A Hatton, H B Woffendin, M Koukoulaki, T C Freeman, D R W Jayne, A N Chaudhry, K G C Smith*

**1214** Synovial immunopathology in haemochromatosis arthropathy  
*G R Heiland, E Aigner, T Dallos, E Sahinbegovic, V Krenn, C Thaler, G Weiss, J H Distler, C Datz, G Schett, J Zwerina*

**1220** Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease  
*E Tourkina, M Richard, J Oates, A Hofbauer, M Bonner, P Gööz, R Visconti, J Zhang, S Znoyko, C M Hatfield, R M Silver, S Hoffman*

**1227** Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis  
*G Zhai, R Wang-Sattler, D J Hart, N K Arden, A J Hakim, T Illig, T D Spector*

**1232** Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout  
*W Urano, A Taniguchi, N Anzai, E Inoue, Y Kanai, M Yamataka, H Endou, N Kamatani, H Yamataka*

**1235** Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjögren's syndrome  
*P Vogelsang, J G Brun, G Øijordsbakken, K Skarstein, R Jonsson, S Appel*

**1239** Loss of imprinting of *IGF2* characterises high *IGF2* mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis  
*A Martin-Trujillo, J G I van Rietschoten, T C G Timmer, F M Rodriguez, T W J Huizinga, P P Tak, S Marsal, S M Ibrahim, B A C Dijkmans, T C T M van der Pouw Kraan, C L Verweij*

**1243** The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene tumour necrosis factor receptor type 1-associated death domain (*TRADD*)  
*J J Pointon, D Harvey, T Karaderi, L H Appleton, C Farrar, M A Stone, R D Sturrock, J D Reveille, M H Weisman, M M Ward, M A Brown, B P Wordworth*

**1247** Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus  
*K Kim, S-K Cho, A Sestak, B Namjou, C Kang, S-C Bae*

### Letters

**1251** Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study  
*J Cavanagh, C Paterson, J McLean, S Pimlott, M McDonald, J Paterson, D Wyper, I McInnes*

**1252** The *SLC22A12* gene is associated with gout in Han Chinese and Solomon Islanders  
*H-P Tu, C-J Chen, C-H Lee, S Tovosia, A M-S Ko, S-J Wang, T-T Ou, G-T Lin, S-L Chiang, H-C Chiang, P-H Chen, S-J Chang, H-M Lai, Y-C Ko*

**1254** Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement  
*J Saech, K Owczarzyk, S Rösigen, H Petereti, M Hallek, A Rubbert-Roth*

**1255** Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care  
*H J E M Janssens, M Janssen, E H van de Lisdonk, J Fransen, P L C M van Riel, C van Weel*